Physician

Mark A Marinella, MD

According to 2025 Medicare claims, Mark Marinella, MD (NPI: 1801888482) practices medical oncology in the Dayton-Kettering-Beavercreek, OH market, with the plurality of this provider's patient population coming from Montgomery, OH. This provider's primary affiliated billing organization is DAYTON PHYSICIANS, LLC (NPI: 1902844947; TIN: 203130844) and primary practice location at 45409-1328. Marinella is affiliated with the Health Centers of Ohio ACO LLC (ACO ID: A5411), participating under the MSSP model.

Marinella's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 753 traditional Medicare patients, billed 194,715 HCPCS/CPT codes, and received $4,213,069 in Medicare payments. The top billing code was 78815 (Nuclear medicine study from skull base to mid-thigh with ct scan). Part D data shows 1,853 prescription claims across 285 beneficiaries totaling $7,371,617 in drug costs, led by Brukinsa (Zanubrutinib). 2023 DME data shows 36 claims. Open Payments data shows 141 records totaling $25,447. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,070,761 to $4,213,069. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,180,394 to $7,371,617. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	507	98,440	$1,070,761
2016	559	118,278	$1,291,474
2017	655	147,114	$1,930,540
2018	762	126,151	$2,182,790
2019	786	157,061	$2,658,121
2020	659	122,447	$1,846,379
2021	670	106,765	$1,487,947
2022	681	118,571	$1,815,997
2023	640	161,430	$2,414,998
2024	753	194,715	$4,213,069

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	214	1,105	$1,180,394
2016	200	1,106	$1,495,628
2017	201	1,151	$2,630,138
2018	190	1,159	$2,775,700
2019	167	1,061	$2,555,239
2020	166	1,099	$2,601,104
2021	200	1,379	$3,765,856
2022	198	1,352	$5,596,107
2023	258	1,744	$7,135,367
2024	285	1,853	$7,371,617

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	70	$29,232
2016	N/R	129	$17,190
2017	N/R	121	$14,497
2018	N/R	125	$17,167
2019	N/R	69	$4,539
2020	N/R	83	$4,394
2021	N/R	61	$3,077
2022	N/R	64	$1,519
2023	N/R	36	$5,281
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
78815	Nuclear medicine study from skull base to mid-thigh with ct scan	117	123	$817
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	132	234	$97
96413	Administration of chemotherapy into vein, 1 hour or less	114	461	$96
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	111	152	$60
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	170	488	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Brukinsa	Zanubrutinib	95	2,850	$1,446,333
Ibrance	Palbociclib	58	1,624	$916,841
Calquence	Acalabrutinib Maleate	52	1,560	$803,381
Revlimid	Lenalidomide	39	1,057	$698,467
Lenalidomide	Lenalidomide	58	1,533	$644,041

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	141	$25,447	GlaxoSmithKline, LLC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark A. Marinella, MD?

Tedicare shows public-source Medicare data for Mark A. Marinella, MD (NPI 1801888482), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark A. Marinella, MD have ACO affiliation data?

Mark A. Marinella, MD is shown with ACO affiliation data for Health Centers of Ohio ACO LLC (MSSP, ACO ID A5411).

What billing organization is linked to Mark A. Marinella, MD?

Mark A. Marinella, MD is linked to DAYTON PHYSICIANS, LLC (billing NPI 1902844947) in the available physician profile data.

Does Mark A. Marinella, MD have Open Payments data?

Mark A. Marinella, MD has 141 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.